HUTCHMED (CHINA) LIMIT

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

24 мар 2021 09:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

24 мар 2021 03:00:00 Источник Nasdaq GlobeNewswire

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

04 мар 2021 07:00:02 Источник Nasdaq GlobeNewswire

Chi-Med to Announce 2020 Final Results

03 фев 2021 02:00:00 Источник Nasdaq GlobeNewswire

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

14 янв 2021 05:00:00 Источник Nasdaq GlobeNewswire

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

10 янв 2021 20:00:00 Источник Nasdaq GlobeNewswire